7:30 am Registration and Coffee
8:20 am Chair’s Opening Remarks
8:30 am Industry Leader’s Fireside Chat
9:30 am Driving Automation in Cell Therapy Manufacturing
10:00 am Speed Networking & Morning Refreshments
Translation
Track
Manufacturing
Track
Development & Commercialisation Track
Selecting & Expanding Optimal T Cell Products
Disrupting Current Processes to Shorten
Manufacturing Times
Clinical Development Decision Making
11.00 FasT CAR Technology: New Practice from Lab to Clinic
William Cao, CEO, Gracel
11.00 Strategies to Improve Manufacturing Turnaround Time
Ali Mohamed, VP, CMC, Immatics
11.00 Strategies for Acceleration of Cell Therapies into the Clinic
Richard Zajicek, Medicine and Process Delivery Leader, GlaxoSmithKline
11:30 Evaluating Cell Potency with Single Cell Proteomics – Polyfunctionality and Correlation with Clinical Outcome
Will Singleterry, Director, Collaborations, Cancer Immunology Team, IsoPlexis
11:30 Automated Cell Therapy Manufacturing Using the CliniMACS Prodigy
Nicolas Danzenbaecher, Senior Product Manager, Miltenyi Biotec
11.30 Translating Academia to Industry - Multi-tumourassociated Antigen-specific (MultiTAA) T Cells
Mythili Koneru, Senior Vice President, Clinical Development, Marker Therapeutics
12.00 Empowering T Cell Therapies through Pharmacologic
Regulation of Engineered Immunomodulatory Factors
Steven Shamah, SVP, Scientific Affairs & Technology, Obsidian Therapeutics
12.00 Towards Proof of Concept of TEGs Based on a Point-of-care Manufacturing Model
Marleen Van Loenen, Director Non-Clinical Development, Gadeta
12.00 Delivery of Advanced Therapies in the UK Landscape
Fiona Thistlethwaite, Medical Oncology Consultant & Director of iMATCH
Translation Track
Selecting & Expanding Optimal T Cell Products
11.00 FasT CAR Technology: New Practice from Lab to Clinic
• FasT CAR technology enables overnight cell manufacturing, setting up new industry standards
• Preclinical study reveals superior CAR-T cell characteristics in contrast to conventional CAR-T cells
• Beyond CD19, FasT CAR technology is broadly applicable to CAR-Ts against other targets
• Safety profile and efficacy of FasT CAR-19 investigational study
William Cao, CEO, Gracell
11.30
12.00 Hurdles for Off-the-Shelf CAR-T Therapies Using Invariant NKT Cells
• Development of the CARNKT platform against haematological and solid tumour malignancies
• Engineered products to secrete cytokines that further enhance persistence and solid tumour activity
• Explore strategies to overcome immunogenicity and enhance persistence and potency
Stefanos Theoharis, SVP, Corporate Development & Partnering, Cell Medica
Manufacturing Track
Disrupting Current Processes to Shorten Manufacturing Times
11.00 Strategies to Improve Manufacturing Turnaround Time
• Discuss the risk of disrupting regulatory norms to revolutionise timescale to 1-5 days
• Review data to decipher whether it is possible to carry out release testing before material is placed into manufacturing machinery
• Outline QA test or electronic test records to speed up the availability of drugs
Ali Mohamed, VP, CMC, Immatics
11.30
12.00 Towards Proof of Concept of TEGs Based on a Point-of-care Manufacturing Model
• Analyse the recoveries of cells in different patient populations, alongside the levels of viable cell production, after infusion to understand how culture conditions can affect expansion
• Automating manufacture to reduce cost and time of production
Tol Trimborn, COO, Gadeta
Development & Commercialisation Track
Clinical Development Decision Making
11.00 Strategies for Acceleration of Cell Therapies into the Clinic
• Discuss science and risk-based approaches to getting cell therapy ready for the clinic
• Outline the importance of multidisciplinary collaborations which are critical to finding efficiencies
• Provide commentary on development pathway for next generation of a lead asset
Delfi Krishna, Director, Strategy, Portfolio, Operations, Cell & Gene Therapy Platform, GlaxoSmithKline
11:30 Translating Academia to Industry - Multi-tumourassociated Antigen-specific (MultiTAA) T Cells
• MultiTAA recognize multiple antigens via native TCR without genetic engineering due to selection process during manufacturing
• Since lymphodepletion is not required for MultiTAA T cell approach, not only is tumor eliminated via direct killing by infused T cells, but also through recruitment of the endogenous immunity
• Clinical data for both hematological malignancies and solid tumors shows both the safety and efficacy of MultiTAA approach
Mythili Koneru, Senior Vice President, Clinical Development, Marker Therapeutics
12.00 Delivery of Advanced Therapies in the UK Landscape
• Establishing the Advanced Therapy Treatment Centre (ATTC) Network Infrastructure
• Collaborative approach across commercial, clinical and academic partners
• Scale-up of activities across the UK
Fiona Thistlethwaite, Medical Oncology Consultant & Director of iMATCH
12:30 pm Lunch & Networking
Translation
Track
Manufacturing
Track
Development & Commercialisation Track
Selecting & Expanding Optimal T Cell Products
Disrupting Current Processes to Shorten
Manufacturing Times
Clinical Development Decision Making
13.30 Clinical Use of Gamma-delta T Cells to Treat Haematological Malignancies – Translation to Phase 3
Michael Leek, CEO, TCBiopharm
13.30 Two-day Manufacturing and Release of T Cells Genetically Modified with Sleeping Beauty System
Laurence Cooper, CEO, Ziopharm Oncology
13.30 Building Flexibility in Clinical Trial Structure to
Meet Unique Trial Needs
Reuben Benjamin, Consultant Haematologist, Kings College
Hospital, NHS
CMC Control to Develop Consistent Quality Products
Regulatory Guidance to Initiate Clinical Trials in Europe
14:00 Fitting Products to Processes: De-risking Raw Materials to Enhance Scalability
Lindsey Clarke, Head of Cell & Gene Therapy EMEA, Bio-Techne Corporation
14:00Collection of Starting Product for Cell Processing and Production
Scott Carter, VP, Field Operations and Customer Relations, KeyBiologics
14:00 Navigating GMO & Environmental Requirements
Jacquelyn Awigena-Cook, Associate Director, Regulatory Policy & Intelligence, EMEA Regulatory Affairs, Celgene
Overcome Tumour Resistance to Improve Durability of Response
14:30 CT053, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Long-term Results from a Phase I Study
Hong Ma, SVP, Clinical Development, CARsgen Therapeutics
14:30 Standardising Raw Material & their Supply
Manel Juan, Head of Immunotherapy Platform, Barcelona Children's Hospital and Hospital Clinic
14.30 Navigating the Regulatory System for an ATMP
John Johnston, Clinical Assessor, MHRA
Translation Track
Selecting & Expanding Optimal T Cell Products
13.30 Clinical Use of Gamma-delta T Cells to Treat Haematological Malignancies – Translation to Phase 3
• What’s special about gamma-deltas?
• Building an allogeneic cell therapy platform – clinical and
regulatory considerations
• Overcoming logistic challenges of allogeneic approaches
Michael Leek, CEO, TCBiopharm
14.00
Overcome Tumour Resistance to Improve Durability of Response
14:30 CT053, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Long-term Results from a Phase I Study
• Patients with relapsed and refractory multiple myeloma have poor prognoses despite latest treatment advance
• CT053, a fully human anti-BCMA CAR-T cell is being developed to address the following issues: (1) significant
adverse events observed in other BCMA programs; (2) lack of durable response in the high-risk population; (3) lack of persistence of CAR T cells with a non-human anti-BCMA CAR construct; and (4) patients may relapse after other anti-BCMA modalities
• CT053, BCMA CAR-T proof of concept phase I clinical trial results with long-term follow-up will be reported
Hong Ma, SVP, Clinical Development, CARsgen Therapeutics
Manufacturing Track
Disrupting Current Processes to Shorten Manufacturing Times
13.30 Two-day Manufacturing and Release of T Cells Genetically Modified with Sleeping Beauty System
• T cells under IND can be genetically modified using the nonviral Sleeping Beauty system to express chimeric antigen
receptor (CAR) to redirect specificity for hematologic malignancies
• The Sleeping Beauty system can be adapted to express cytokines in addition to immunoreceptors
• The co-expression of membrane-bound IL-15 (mbIL15) and CAR enables resting T cells from the peripheral blood to be
produced and infused within 2 days under an IND using the Sleeping Beauty system using an approach called “rapid
personalised manufacture” (RPM)
Laurence Cooper, CEO, Ziopharm Oncology
CMC Control to Develop Consistent Quality Products
14.00
14:30 Round Table Discussion: Standardising Raw Material & their Supply
• Review the availability of raw materials and variability
• Discuss the need to normalise raw materials including
patient materials and culture material
Development & Commercialisation Track
Regulatory Guidance to Initiate Clinical Trials in Europe
13.30 Round Table Discussion: Building a Regulatory Strategy for Global Clinical Trials
• Outline the different types of authorities that require approval
• Experience working with various European countries
• Considerations for which country to start trials in to ensure clinical growth and timely execution
• Review the framework in Europe for new innovations
14:00 Round Table Discussion: Building a Regulatory Strategy for Global Clinical Trials - CONTINUED...
14:30 Navigating GMO & Environmental Requirements
• Insights into GMO submission processes across different countries in context of ATMP
• Overview of recent developments to streamline GMO submission and assessment process for ATMPs in Europe
• Recommendations for alignment with CTA process in context of forthcoming implementation of Clinical Trials Regulation
Jacquelyn Awigena-Cook, Associate Director, Regulatory Policy & Intelligence, EMEA Regulatory Affairs, Celgene
3:00 pm Poster Session
Synopsis
Share your work with the pioneers of CAR-TCR therapeutic development! Bring a poster and gain feedback on your latest research with this
expert community. Growing through popular demand, this exciting session brings you hot new data highlighting innovating research
3:30 pm Tech Slam @ Innovation Hub
4:00 pm Afternoon Refreshments
Translation
Track
Manufacturing
Track
Development & Commercialisation Track
Toxicity Management
CMC Control to Develop Consistent Quality Products
Early Evidence Criteria to Achieve Access & Reimbursement
16:30 Mechanisms, Predictive Markers and Progress with Management of Axicelrelated Toxicities
Adrian Bot, VP, Translational Medicine, Kite, a Gilead Company
16:30 CMC for CAR-TCR Therapies – Shifting the Quality Paradigm
Michael Lehmicke, Director, Science & Industry Affairs, Alliance for Regenerative Medicine
16:30 Evidence Generation and Access to CAR-T Therapies: A Health Technology Assessment Approach
Deborah Morrison, Principal Scientific Advisor, National Institute for Health & Care Excellence
Overcoming Vector Supply Bottlenecks
17:00 Biomarkers in the era of Cell & Gene therapy
Ken Morrison, Vice President Portfolio Analytics and Growth, Oncology, Covance
17:00 To Go Viral, or To Go Non-Viral, That is the Question for Cell Modification
Stefano Baila, Director of Operations and Business Development, Amenocyte
17.00 Early Evidence Needs to Improve Access and Commercial Potential of CAR-TCR products
Aura Mackenzie Senior Director, AVES, Market Access, bluebird bio
17:30 Translational Strategies to Prevent Toxicity
Jingyi Xiang, Director, Strategy & Business Development, Eureka Therapeutics
17:30 Overcoming Challenges in Obtaining High, Quality Sustainable Vector Supply
Cindy Jung, Director, Vector Process Development, GlaxoSmithKline
17.30 Can We Afford a Cure ? Innovative Reimbursement Payment Over Time Models Based on Remission
Omar Ali, Visiting Lecturer, Value Based Pricing & Former Adviser to NICE, University of Portsmouth
Translation Track
Toxicity Management
16:30 Mechanisms, Predictive Markers and Progress with Management of Axi-cel related Toxicities
• Explore the mechanism of toxicity and strategies to
manage it with early clinical biomarkers and immunemonitoring tests
• Review clinical outcomes of combination trials to manage
safety without interfering with clinical efficacy
Adrian Bot, VP, Translational Medicine, Kite, a Gilead Company
17:00 Translational Strategies to Prevent Toxicity
• Discuss the need to overcome CRS and NT to enable the delivery of these therapies in an outpatient setting
• Review alternative strategies to design the next-gen T-cells with enhanced efficacy and optimised activation and regulatory pathways
• Analyze clinical results outlining reduced CRS and NT
Cheng Liu, CEO, Eureka Therapeutics
Manufacturing Track
CMC Controls to Develop Consistent Quality Products
16:30 CMC for CAR-TCR Therapies – Shifting the Quality Paradigm
• Best practices for the application of Quality by Design (QbD) principles to cell and gene therapy
• Standards development in the areas of starting materials, cell collection, and supply chain logistics
• Evolving regulatory guidance for CMC - compare and contrast EMA to FDA
Michael Lehmicke, Director, Science & Industry Affairs, Alliance for Regenerative Medicine
Overcome Vector Supply Bottlenecks
17:00 Overcoming Challenges in Obtaining High, Quality Sustainable Vector Supply
• Holistic view in terms of vector, formulation, clearance and lead
• Experience sourcing vector supply as a raw material and building up with a global supply chain
• Outline which grade of vector, and type, should make up a final product
Amol Ketkar, VP, Cell & Gene Therapy & Product Development, GlaxoSmithKline
Development & Commercialisation Track
Regulatory Guidance to Initiate Clinical Trials in Europe
16:30 Navigating the Regulatory System for an ATMP
• Outline how different national agencies have different attitudes
• Address the need to make early contact with the regulator
• Review the perspective of the regulator, understanding that there will be on-going validation of assays and control over
processes
John Johnston, Clinical Assessor, MHRA
Early Evidence Criteria to Achieve Access & Reimbursement
17:00 Evidence Generation and Access to CAR-T Therapies: A Health Technology Assessment Approach
• Advances in precision medicine, including CAR-T therapies, mean treatments are becoming increasingly tailored to
individuals with patients being offered more personalised therapeutic options
• CAR-Ts have a disruptive impact on current health delivery processes leading to capacity issues in some therapeutic areas
• Early/limited evidence generation impacts the health technology assessment and economic evaluation of these agents necessitating novel approaches to funding and adoption
• Address how these complexities are being managed and where further work is needed
Deborah Morrison, Principal Scientific Advisor, National Institute for Health & Clinical Excellence